

Monday 5 September 2022
ASX Announcement

Second US Patent granted providing broad and significant protection for the use of Glucoprime® on any skin condition

- **Granting of Tissue Repair Ltd's second US patent provides broad protection for the use of TR-987® and Glucoprime® on any skin condition including burns, chronic wounds, surgical wounds, pressure ulcers and any post procedure wound whether surgical or cosmetic**
- **The granting of the patent strengthens the current commercialization of TR Pro+™ both globally and in Australia**

Tissue Repair Limited ("TR") is one of a select number of advanced biotechnology companies globally seeking to enter a phase 3 program in venous leg ulcers. If the trials for its lead drug candidate TR-987® are successful, the Company will be the first drug approved for venous leg ulcers in over 25 years, a large and growing market with a similar cost to treat of some cancers.

TR is pleased to announce that its USA patent application 17/845,098, with claims for use of the Company's Active Pharmaceutical Ingredient (API) Glucoprime® for topically applied methods of treating any skin condition, has been allowed by the US Patent and Trademark Office (USPTO).

Glucoprime® is the API used in formulating the Company's first drug candidate TR-987® for treatment of venous leg ulcers and is TR Pro+™ a product for post-operative cosmeceutical application in a number of dermatological and related treatments.

TR's Co-Founder Tony Charara said "The patent is significant as it provides broad protection for the use of our proprietary Glucoprime® technology across its current dual focus of Chronic wounds and post procedure cosmetic healing, as well as extending protection into any topically applied skin condition, such as pressure ulcers, diabetic foot ulcers, surgical wounds and burns."

This new patent approval follows the very recent approval of TR's first patent in April 2022, with claims on the method of manufacturing of Glucoprime® (US Patent No. 11,384,160 on 12 July 2022). There are no known alternative processes from which to produce the Company's proprietary biological polysaccharide molecule.

The now allowed portfolio of granted patent applications represent a core component of the Company's IP and protects both the Company's process for the manufacture of its API and its exclusive rights over its intended uses of its unique biological proprietary polysaccharide molecule across a large number of skin conditions in very large markets.



About Tissue Repair

Tissue Repair Limited (ASX TRP) is an advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering a phase III program in chronic wounds for its lead drug candidate TR-987[®] with a secondary focus on commercialising TR Pro+[™] a post procedure topical gel to accelerate healing and improve skin quality post any cosmetic procedure. The Company's longer-term strategy is to commercialize its propriety Glucoprime[®] API to treat a variety of wounds and skin conditions.

For further information in relation to this release please contact Darryl Reed at darryl.reed@trtherapeutics.com 0419 557 663.

This announcement has been approved for release by TRP's board.

**Tissue Repair Ltd**

Level 10, 255 Pitt Street, Sydney, NSW 2000
ACN: 158 411 566